CoChat

GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior

Open access
Samms, Ricardo J., Cosgrove, Richard, Snider, Brandy M., Furber, Ellen C., Droz, Brian A., Briere, Daniel A., Dunbar, James, Dogra, Mridula, Alsina-Fernandez, Jorge, Borner, Tito, De Jonghe, Bart C., Hayes, Matthew R., Coskun, Tamer, Sloop, Kyle W., Emmerson, Paul J., Ai, Minrong · 2022 · Diabetes
Cited by 69

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

The induction of nausea and emesis is a major barrier to maximizing the weight loss profile of obesity medications, and therefore, identifying mechanisms that improve tolerability could result in added therapeutic benefit. The development of peptide YY (PYY)-based approaches to treat obesity are no exception, as PYY receptor agonism is often accompanied by nausea and vomiting. Here, we sought to determine whether glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) agonism reduces PYY-induced nausea-like behavior in mice. We found that central and peripheral administration of a GIPR agonist reduced conditioned taste avoidance (CTA) without affecting hypophagia mediated by a PYY analog. The receptors for GIP and PYY (Gipr and Npy2r) were found to be expressed by the same neurons in the area postrema (AP), a brainstem nucleus involved in detecting aversive stimuli. Peripheral administration of a GIPR agonist induced neuronal activation (cFos) in the AP. Further, whole-brain cFos analyses indicated that PYY-induced CTA was associated with augmented neuronal activity in the parabrachial nucleus (PBN), a brainstem nucleus that relays aversive/emetic signals to brain regions that control feeding behavior. Importantly, GIPR agonism reduced PYY-mediated neuronal activity in the PBN, providing a potential mechanistic explanation for how GIPR agonist treatment reduces PYY-induced nausea-like behavior. Together, the results of our study indicate a novel mechanism by which GIP-based therapeutics may have benefit in improving the tolerability of weight loss agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db21-0848

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 27

  1. Srivastava, 2018, Current pharmacotherapy for obesity, Nat Rev Endocrinol, 14, 12, 10.1038/nrendo.2017.122 · DOI · Paper page
  2. Saper, 2016, The house alarm, Cell Metab, 23, 754, 10.1016/j.cmet.2016.04.021 · DOI
  3. Horn, 2008, Why is the neurobiology of nausea and vomiting so important?, Appetite, 50, 430, 10.1016/j.appet.2007.09.015 · DOI
  4. Andermann, 2017, Toward a wiring diagram understanding of appetite control, Neuron, 95, 757, 10.1016/j.neuron.2017.06.014 · DOI · Paper page
  5. Miller, 1994, The area postrema and vomiting, Front Neuroendocrinol, 15, 301, 10.1006/frne.1994.1012 · DOI · Paper page
  6. Chen, 2018, Parabrachial CGRP neurons establish and sustain aversive taste memories, Neuron, 100, 891, 10.1016/j.neuron.2018.09.032 · DOI · Paper page
  7. Adriaenssens, 2020, The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system, Peptides, 125, 170194, 10.1016/j.peptides.2019.170194 · DOI · Paper page
  8. Costa, 2022, Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation, Mol Metab, 55, 101407, 10.1016/j.molmet.2021.101407 · DOI · Paper page
  9. Hayes, 2021, The role of GIP in the regulation of GLP-1 satiety and nausea, Diabetes, 70, 1956, 10.2337/dbi21-0004 · DOI · Paper page
  10. le Roux, 2008, Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake, Ann Clin Biochem, 45, 93, 10.1258/acb.2007.007068 · DOI · Paper page
  11. Halatchev, 2005, Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice, Cell Metab, 1, 159, 10.1016/j.cmet.2005.02.003 · DOI · Paper page
  12. Rangwala, 2019, A long-acting PYY3-36 analog mediates robust anorectic efficacy with minimal emesis in nonhuman primates, Cell Metab, 29, 837, 10.1016/j.cmet.2019.01.017 · DOI · Paper page
  13. Briere, 2018, Mechanisms to elevate endogenous GLP-1 beyond injectable GLP-1 analogs and metabolic surgery, Diabetes, 67, 309, 10.2337/db17-0607 · DOI · Paper page
  14. Worth, 2020, The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling, eLife, 9, e55164, 10.7554/eLife.55164 · DOI · Paper page
  15. Perens, 2021, An optimized mouse brain atlas for automated mapping and quantification of neuronal activity using iDISCO+ and light sheet fluorescence microscopy, Neuroinformatics, 19, 433, 10.1007/s12021-020-09490-8 · DOI
  16. Palmiter, 2018, The parabrachial nucleus: CGRP neurons function as a general alarm, Trends Neurosci, 41, 280, 10.1016/j.tins.2018.03.007 · DOI · Paper page
  17. Gimeno, 2020, Leveraging the gut to treat metabolic disease, Cell Metab, 31, 679, 10.1016/j.cmet.2020.02.014 · DOI · Paper page
  18. Schmidt, 2014, Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men, Am J Physiol Endocrinol Metab, 306, E1248, 10.1152/ajpendo.00569.2013 · DOI · Paper page
  19. Neary, 2005, Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively, Endocrinology, 146, 5120, 10.1210/en.2005-0237 · DOI · Paper page
  20. De Silva, 2011, The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans, Cell Metab, 14, 700, 10.1016/j.cmet.2011.09.010 · DOI · Paper page
  21. Geisler, 2020, GIP receptor agonism attenuates GLP-1 receptor agonist induced nausea in rodents, Obesity (Silver Spring), 28, 103
  22. Rodriguez, 2019, Identifying parabrachial neurons selectively regulating satiety for highly palatable food in mice, eNeuro, 6, 10.1523/ENEURO.0252-19.2019 · DOI
  23. Stein, 2010, Area postrema projects to FoxP2 neurons of the pre-locus coeruleus and parabrachial nuclei: brainstem sites implicated in sodium appetite regulation, Brain Res, 1359, 116, 10.1016/j.brainres.2010.08.085 · DOI · Paper page
  24. Geerling, 2016, Genetic identity of thermosensory relay neurons in the lateral parabrachial nucleus, Am J Physiol Regul Integr Comp Physiol, 310, R41, 10.1152/ajpregu.00094.2015 · DOI · Paper page
  25. Kim, 2020, A neural circuit mechanism for mechanosensory feedback control of ingestion, Nature, 580, 376, 10.1038/s41586-020-2167-2 · DOI
  26. Chiang, 2020, Divergent neural pathways emanating from the lateral parabrachial nucleus mediate distinct components of the pain response, Neuron, 106, 927, 10.1016/j.neuron.2020.03.014 · DOI · Paper page
  27. Ryan, 2017, Oxytocin-receptor-expressing neurons in the parabrachial nucleus regulate fluid intake, Nat Neurosci, 20, 1722, 10.1038/s41593-017-0014-z · DOI · Paper page

Cited by

See all 69

Metadata

Authors
Samms, R. J., Cosgrove, R., Snider, B. M., Furber, E. C., Droz, B. A., Briere, D. A., Dunbar, J., Dogra, M., Alsina-Fernandez, J., Borner, T., De Jonghe, B. C., Hayes, M. R., Coskun, T., Sloop, K. W., Emmerson, P. J., & Ai, M.
Venue
Diabetes
Published
2022-05-02
Volume
71
Issue
7
Pages
1410-1423
ISSN
0012-1797 (ISSN-L)
OpenAlex
W4225280550
Cited by
69
References
16
FWCI
5.54
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior. https://app.cochat.ai/papers/10.2337/db21-0848
The paper
Samms, R. J., Cosgrove, R., Snider, B. M., Furber, E. C., Droz, B. A., Briere, D. A., Dunbar, J., Dogra, M., Alsina-Fernandez, J., Borner, T., De Jonghe, B. C., Hayes, M. R., Coskun, T., Sloop, K. W., Emmerson, P. J., & Ai, M. (2022). GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior. Diabetes. https://doi.org/10.2337/db21-0848

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.